annual cash & cash equivalents:
$517.55M+$379.92M(+276.03%)Summary
- As of today (September 10, 2025), CPRX annual cash & cash equivalents is $517.55 million, with the most recent change of +$379.92 million (+276.03%) on December 31, 2024.
- During the last 3 years, CPRX annual cash & cash equivalents has risen by +$326.29 million (+170.59%).
- CPRX annual cash & cash equivalents is now at all-time high.
Performance
CPRX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$652.80M+$72.14M(+12.42%)Summary
- As of today (September 10, 2025), CPRX quarterly cash & cash equivalents is $652.80 million, with the most recent change of +$72.14 million (+12.42%) on June 30, 2025.
- Over the past year, CPRX quarterly cash & cash equivalents has increased by +$277.11 million (+73.76%).
- CPRX quarterly cash & cash equivalents is now at all-time high.
Performance
CPRX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CPRX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +276.0% | +73.8% |
| 3 y3 years | +170.6% | +195.7% |
| 5 y5 years | +447.6% | +467.4% |
CPRX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +276.0% | at high | +439.6% |
| 5 y | 5-year | at high | +447.6% | at high | +467.4% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
CPRX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $652.80M(+12.4%) |
| Mar 2025 | - | $580.66M(+12.2%) |
| Dec 2024 | $517.55M(+276.0%) | $517.55M(+17.0%) |
| Sep 2024 | - | $442.33M(+17.7%) |
| Jun 2024 | - | $375.69M(+21.0%) |
| Mar 2024 | - | $310.41M(+125.5%) |
| Dec 2023 | $137.64M(-53.9%) | $137.64M(+13.8%) |
| Sep 2023 | - | $120.97M(-32.3%) |
| Jun 2023 | - | $178.79M(+20.6%) |
| Mar 2023 | - | $148.25M(-50.3%) |
| Dec 2022 | $298.39M(+56.0%) | $298.39M(+16.5%) |
| Sep 2022 | - | $256.06M(+16.0%) |
| Jun 2022 | - | $220.79M(+11.6%) |
| Mar 2022 | - | $197.80M(+3.4%) |
| Dec 2021 | $191.27M(+36.3%) | $191.27M(+9.4%) |
| Sep 2021 | - | $174.79M(+12.6%) |
| Jun 2021 | - | $155.28M(+8.4%) |
| Mar 2021 | - | $143.30M(+2.2%) |
| Dec 2020 | $140.28M(+48.4%) | $140.28M(+10.4%) |
| Sep 2020 | - | $127.11M(+10.5%) |
| Jun 2020 | - | $115.05M(+13.1%) |
| Mar 2020 | - | $101.75M(+7.7%) |
| Dec 2019 | $94.52M(+76.7%) | $94.52M(+23.5%) |
| Sep 2019 | - | $76.54M(+27.7%) |
| Jun 2019 | - | $59.92M(+31.3%) |
| Mar 2019 | - | $45.63M(-14.7%) |
| Dec 2018 | $53.48M(-36.3%) | $53.48M(-13.3%) |
| Sep 2018 | - | $61.66M(-9.9%) |
| Jun 2018 | - | $68.41M(-12.2%) |
| Mar 2018 | - | $77.94M(-7.2%) |
| Dec 2017 | $84.01M(+107.9%) | $84.01M(+147.8%) |
| Sep 2017 | - | $33.91M(-3.5%) |
| Jun 2017 | - | $35.13M(-3.8%) |
| Mar 2017 | - | $36.53M(-9.6%) |
| Dec 2016 | $40.41M(-30.8%) | $40.41M(-9.7%) |
| Sep 2016 | - | $44.74M(-6.8%) |
| Jun 2016 | - | $48.02M(-8.4%) |
| Mar 2016 | - | $52.45M(-10.2%) |
| Dec 2015 | $58.40M | $58.40M(-7.3%) |
| Sep 2015 | - | $62.96M(-6.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | - | $67.40M(-5.8%) |
| Mar 2015 | - | $71.54M(+82.1%) |
| Dec 2014 | $39.28M(+65.6%) | $39.28M(-5.2%) |
| Sep 2014 | - | $41.45M(-7.9%) |
| Jun 2014 | - | $45.01M(+111.5%) |
| Mar 2014 | - | $21.28M(-10.2%) |
| Dec 2013 | $23.71M(+53.8%) | $23.71M(-14.3%) |
| Sep 2013 | - | $27.65M(+143.2%) |
| Jun 2013 | - | $11.37M(-13.6%) |
| Mar 2013 | - | $13.16M(-14.6%) |
| Dec 2012 | $15.42M(+155.7%) | $15.42M(+28.8%) |
| Sep 2012 | - | $11.97M(+59.3%) |
| Jun 2012 | - | $7.51M(+59.1%) |
| Mar 2012 | - | $4.72M(-21.7%) |
| Dec 2011 | $6.03M(+10.1%) | $6.03M(+45.1%) |
| Sep 2011 | - | $4.16M(-23.2%) |
| Jun 2011 | - | $5.41M(-21.3%) |
| Mar 2011 | - | $6.87M(+25.5%) |
| Dec 2010 | $5.48M(-29.6%) | $5.48M(-12.4%) |
| Sep 2010 | - | $6.25M(+11.4%) |
| Jun 2010 | - | $5.61M(-17.0%) |
| Mar 2010 | - | $6.76M(-13.1%) |
| Dec 2009 | $7.78M(-33.9%) | $7.78M(+58.4%) |
| Sep 2009 | - | $4.91M(-21.6%) |
| Jun 2009 | - | $6.27M(-29.8%) |
| Mar 2009 | - | $8.93M(-24.1%) |
| Dec 2008 | $11.77M(-26.2%) | $11.77M(-21.7%) |
| Sep 2008 | - | $15.03M(+14.9%) |
| Jun 2008 | - | $13.08M(-11.1%) |
| Mar 2008 | - | $14.72M(-7.7%) |
| Dec 2007 | $15.94M(-22.0%) | $15.94M(-5.6%) |
| Sep 2007 | - | $16.89M(-4.1%) |
| Jun 2007 | - | $17.60M(-7.7%) |
| Mar 2007 | - | $19.06M(+534.8%) |
| Dec 2006 | $20.43M(+2550.1%) | - |
| Sep 2006 | - | $3.00M(+826.4%) |
| Jun 2006 | - | $324.20K(-58.0%) |
| Dec 2005 | $771.10K(+319.3%) | $771.10K(+319.3%) |
| Dec 2004 | $183.90K(+71.7%) | $183.90K |
| Dec 2002 | $107.10K | - |
FAQ
- What is Catalyst Pharmaceuticals, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Catalyst Pharmaceuticals, Inc.?
- What is Catalyst Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
- What is Catalyst Pharmaceuticals, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Catalyst Pharmaceuticals, Inc.?
- What is Catalyst Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
What is Catalyst Pharmaceuticals, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of CPRX is $517.55M
What is the all time high annual cash & cash equivalents for Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $517.55M
What is Catalyst Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, CPRX annual cash & cash equivalents has changed by +$379.92M (+276.03%)
What is Catalyst Pharmaceuticals, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of CPRX is $652.80M
What is the all time high quarterly cash & cash equivalents for Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $652.80M
What is Catalyst Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, CPRX quarterly cash & cash equivalents has changed by +$277.11M (+73.76%)